Discontinued ProductOlmesartan medoxomil (Cat. No. 4620) has been withdrawn from sale for commercial reasons.
Prodrug metabolised in vivo to Olmesartan (Cat. No. 4616), a selective non-peptide angiotensin II type I receptor (AT1) antagonist. Selectively inhibits angiotensin II binding to AT1 receptors in bovine adrenal cortical membranes (IC50 = 7.7 nM), with no effect on AT2 receptors.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
References are publications that support the biological activity of the product.
Kim et al (1997) Effects of angiotensin AT1 receptor antagonist on volume overload-induced cardiac gene expression in rats. Hypertens.Res. 20 133 PMID: 9220278
Mizuno et al (1995) Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur.J.Pharmacol. 285 181 PMID: 8566137
View Related Products by Product Action
Keywords: Olmesartan medoxomil, Olmesartan medoxomil supplier, CS866, antagonists, RNH-6270, AT1, receptors, angiotensin, II, type, I, receptor, Angiotensin, Receptors, 4620, Tocris Bioscience
Citations for Olmesartan medoxomil
Citations are publications that use Tocris products.
Currently there are no citations for Olmesartan medoxomil.
Reviews for Olmesartan medoxomil
There are currently no reviews for this product. Be the first to review Olmesartan medoxomil and earn rewards!
Have you used Olmesartan medoxomil?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.